Gynecological Means

Trade name: Cyclogest® Active ingredient (INN): progesterone Dosage form: pessaries for vaginal and rectal use Compound: Each pessary contains: active substance: progesterone – 200 mg or 400 mg. excipients: solid fatty base. Description: torpedo-shaped pessaries, almost white, about 30 mm long, about 10 mm in diameter. Pharmacotherapeutic group: sex hormones and modulators of the reproductive system. Progestogens. Derivatives of pregnene. Progesterone ATX code: G03DA04 By stimulating protein lipase, it increases fat reserves and increases glucose utilization. By increasing the concentration of basal and stimulated insulin, it promotes the accumulation of glycogen in the liver and increases the production of gonadotropic hormones of the pituitary gland; reduces azotemia, increases nitrogen excretion in urine. Pharmacokinetics Absorption occurs quickly, a high concentration of progesterone is observed 1 hour after administration. Cmax of progesterone in blood plasma is achieved 2-6 hours after administration. When the drug is administered at a dose of 100 mg 2 times a day, the average concentration remains at 9.7 ng/ml for 24 hours. When administered in doses of more than 200 mg/day, the concentration of progesterone corresponds to the first trimester of pregnancy. Plasma protein binding is 90%. Progesterone accumulates in the uterus. Metabolized to form predominantly 3-alpha, 5-beta-pregnanediol. The concentration of 5-beta-pregnanolone in the blood plasma does not increase. It is excreted in the urine in the form of metabolites, the main part being 3-alpha, 5-beta-pregnanediol (pregnandione). This is confirmed by a constant increase in its concentration (Cmax 142 ng/ml after 6 hours). Indications for use Progesterone deficiency conditions in women: -menopausal hormonal therapy in case of progesterone deficiency with non-functioning (absent) ovaries (egg donation); prevention (prevention) of premature birth in women at risk (with shortening of the cervix and/or anamnestic data of premature birth and/or premature rupture of the membranes); -support of the luteal phase during preparation for in vitro fertilization; - support of the luteal phase in the spontaneous or induced menstrual cycle; -premature menopause; -menopausal hormone therapy (in combination with estrogen-containing drugs); - infertility due to luteal insufficiency; - threatened abortion or prevention of habitual abortion due to progesterone deficiency. Directions for use and doses Pessaries are administered intravaginally or rectally at 200 mg to 400 mg twice daily. Prevention (prophylaxis) of preterm birth in women at risk (with shortening of the cervix and/or history of preterm labor and/or premature rupture of membranes): the usual dose is 200 mg at bedtime, from the 22nd to the 34th week pregnancy. Complete absence of progesterone in women with non-functioning (absent) ovaries (egg donation): against the background of estrogen therapy, 100 mg/day on the 13th and 14th days of the cycle, then 100 mg 2 times/day from the 15th to On the 25th day of the cycle, from the 26th day and if pregnancy is detected, the dose increases by 100 mg/day every week, reaching a maximum of 600 mg/day, divided into 3 doses. The indicated dose is usually used for 60 days. Support of the luteal phase during the in vitro fertilization cycle: it is recommended to use from 200 to 600 mg/day, starting from the day of human chorionic gonadotropin injection during the first and second trimesters of pregnancy. Support of the luteal phase in a spontaneous or induced menstrual cycle, in case of infertility associated with dysfunction of the corpus luteum: it is recommended to use 200-300 mg/day, starting from the 17th day of the cycle for 10 days, in case of delayed menstruation and diagnosis of pregnancy, treatment should to be continued. In cases of threatened abortion or in order to prevent habitual abortion occurring against the background of progesterone deficiency: 200-400 mg/day in 2 divided doses daily in the first and second trimesters of pregnancy. Drug interactions The interaction of progesterone with other drugs when administered intravaginally or rectally has not been evaluated. The simultaneous use of other drugs administered intravaginally or rectally should be avoided to avoid interfering with the release and absorption of progesterone. Release form 5 pessaries are placed in contour packages made of polyvinyl chloride/polyethylene film. 3 contour packages together with instructions for medical use in the state and Russian languages ​​are placed in a cardboard pack. Storage conditions Store in original packaging, protected from light at a temperature not exceeding 30 °C. Keep out of the reach of children. Best before date 4 years. Do not take after the expiration date stated on the package. Conditions for dispensing from pharmacies On prescription. Manufacturer Accord-UK Ltd. Barnstaple, EX32 8NS, UK, under license from L.D. Collins & Co. Ltd.” 1st Floor, Gallery Court, 28 Arcadia Avenue, London, N3 2FG, UK.

COMPOUND: Each capsule contains 300 mg of highly purified broccoli indole-3 carbinol, concentrate broccoli cabbage from the cruciferous family 92.5 mg. PHARMACOLOGICAL FEATURES; Evadol is a universal corrector of sexual hyperplastic processes in the organs and tissues of the female reproductive system (breast, endometrium, myometrium, cervix, ovaries). Normalizes the balance of estrogens in the body and suppresses their negative stimulating effects, and also blocks other (hormone-independent) mechanisms that activate pathological cellular growth in the tissues of the mammary gland and uterus. It has the ability to cause selective death of transformed cells with abnormally high proliferative activity. Indole is obtained from plants of the cruciferous family. It belongs to the group of antiestrogenic and antitumor drugs of plant origin. Evadol has an anti-estrogenic effect by restoring normal metabolism of the female sex hormone estradiol and inhibiting the formation of 16-hydroxystrone, which has an oncogenic (promoting the formation of malignant tumors) effect on the woman’s body. At the same time, it suppresses the function of estrogen receptors (nerve endings sensitive to estrogen) in target tissues. This effect of indole allows it to be used for various functional disorders caused by increased levels of estrogen in the blood. Many tumors and pre-tumor diseases of the female genital area and mammary glands have a clear dependence on the amount of estrogens produced in the body. These are mastopathy, breast cancer, uterine fibroids, uterine cancer, endometriosis and so on.   Evadol is able to suppress tissue hyperproliferation (rapid cell proliferation associated with tumor growth) of epithelial origin in the female reproductive system, caused by disturbances in the regulation of cell division. This leads to suppression of the growth of estrogen-dependent tumors of the female reproductive system. At the same time, it promotes the selective destruction (apoptosis) of tumor cells and neutralizes the effect of substances that stimulate the development of mammary tumors. Evadol also exhibits activity against diseases associated with the human papillomavirus (HPV) and suppresses the process of transformation of diseases caused by this virus into malignant tumors, that is, the process of malignancy. The effect of Evadol is enhanced by broccoli concentrate. This allows you to achieve high results after the first course of treatment. Broccoli contains a special substance r::,.;lforaphane, which stops the growth of cancer cells. Another component of broccoli - sinegrin - secretes a substance that stops the division of cancer cells and causes their death. In addition, broccoli is rich in iodine and is an effective preventative against breast cancer. Women who consume this cabbage regularly note not only a decrease in pain in the mammary gland, but also the resorption of small lumps. Also, a rich set of vitamins, such as C, PP, K, U and beta-carotene, helps the body maintain the normal hormone prolactin, which prevents the development of seals and the formation of cysts. INDICATIONS: Evadol is used in combination with traditional treatment methods (including chemotherapy and radiation therapy, surgical methods, immunomodulators, etc.) for diseases of the female reproductive system, the development of which is based on the processes of pathological cell proliferation. Evadol can be used in women for the prevention of hormonal disorders and hormone-dependent diseases, incl. oncological: mastopathy; endometriosis, adenomyosis; myoma (fibroids) of the uterus; ovarian cyst; dysplasia and cervical cancer; premenstrual syndrome; ovarian cancer; mammary cancer. papillomatosis of the female reproductive system, papillomavirus infection (papillomas, genital warts, respiratory papillomatosis), adenomyosis, uterine fibroids and endometrial hyperplasia without atypia, as well as for the prevention of relapses of these diseases after surgical treatment.   CONTRAINDICATIONS: - individual intolerance (including a history of hypersensitivity) to indole-3-carbinol; - not recommended for persons taking medications that reduce the acidity of gastric juice; - strictly contraindicated during pregnancy and lactation. SIDE EFFECTS: Evadol is well tolerated and does not cause side effects at therapeutic doses. USE DURING PREGNANCY AND LACTATION: The drug is strictly contraindicated during pregnancy and lactation! DOSES AND RULES OF APPLICATION: Evadol is prescribed orally before or during meals, 300 mr (1 capsule) daily for 3-6 months. For mastopathy Evado! take 1 capsule 1 time per day for 6 months, for the purpose of prevention – 1 capsule 1 time per day for 3 months.   For endometriosis and uterine fibroids, Evadol is used in complex treatment, 1 capsule once a day for 6 months; in order to prevent relapses, 1 capsule 1 time per day for 3 months. For all forms of human papillomavirus infection, Evadol is used in combination with immunomodulatory or antiviral drugs, 1 capsule once a day for 6 months. STORAGE CONDITIONS: Store at temperatures up to 25°C, in a dry place out of reach of children. RELEASE FORM: Evadol, capsule No. 60. Not a medicine. Dietary supplement CONDITIONS OF DISCHARGE FROM PHARMACIES: Dispensed without a doctor's prescription.